Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Depreciation & Amortization (CF) (2016 - 2025)

Surgery Partners' Depreciation & Amortization (CF) history spans 12 years, with the latest figure at $59.9 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 76.7% year-over-year to $59.9 million; the TTM value through Dec 2025 reached $176.0 million, up 15.33%, while the annual FY2025 figure was $176.0 million, 15.33% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $59.9 million at Surgery Partners, up from $39.5 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $59.9 million in Q4 2025 and bottomed at $22.7 million in Q4 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $30.4 million (2022), against an average of $33.0 million.
  • The largest YoY upside for Depreciation & Amortization (CF) was 76.7% in 2025 against a maximum downside of 21.31% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $22.7 million in 2021, then soared by 30.4% to $29.6 million in 2022, then grew by 5.07% to $31.1 million in 2023, then rose by 9.0% to $33.9 million in 2024, then skyrocketed by 76.7% to $59.9 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's Depreciation & Amortization (CF) are $59.9 million (Q4 2025), $39.5 million (Q3 2025), and $40.3 million (Q2 2025).